Cem BARÇIN, Ümit AYDOĞAN, Tahir İSMAİLOĞLU

DIFFERENCES BETWEEN OFFICE AND AMBULATORY BLOOD PRESSURE MEASUREMENTS IN PATIENTS USING TRIPLE ANTIHYPERTENSIVE TREATMENT

Objectives: It has been suggested that blood pressure (BP) measurements in the office/clinic may fall short of detecting phenomena such as a white coat or masked hypertension (HT). In this cross-sectional study, we aimed to evaluate the differences in office and ambulatory BP measurements (ABPM) and investigate the secondary causes in patients using triple antihypertensive medication. Materials and Methods: Of the included 57 patients using triple antihypertensives, 28 had high office BP measurements (HOM-HT group), whereas 29 had normal office BP values (NOM-HT group). Both groups underwent an ABPM. Also, serum biochemistry, 24-hour urine tests, Epworth Sleepiness Scale, and renal artery Doppler assessments were performed to detect secondary causes of HT. Groups were compared regarding ABPM values, tests, scale results, and secondary causes. Results: No significant differences were found between the demographics and serum tests. According to the ABPM, white coat HT was detected in 15 patients (53.67%) in the HOM-HT group, whereas five (17.24%) in the NOM-HT group had masked HT (p=0.018). In three patients, secondary causes were detected (hyperaldosteronism, renal artery compression, and sleep apnea), all of whom were in the HOM-HT group. The groups did not differ significantly regarding the frequency of secondary causes (p=0.112). In contrast to when the ABPM is taken into account (16.66% vs. 0% p=0.028). Conclusion: Data of the present study showed that ABPM is necessary to detect white coat and masked HT. Also, depending on ABPM rather than office/clinic measurements may save time and expenses when investigating secondary causes.

PDF

___

1. Chobanian AV, Bakris GL, Black HL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289(19):2560-71.
2. Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492.
3. Altun B, Arici M, Nergizoǧlu G, et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens. 2005 Oct;23(10):1817-23.
4. Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:510-26.
5. De La Sierra A, Segura J, Banegas JR, Gorostidi M, De La Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902. 6. Judd E, Calhoun DA. Apparent and true resistant hypertension: Definition, prevalence and outcomes. J Hum Hypertens. 2014 Aug;28(8):463-8.
7. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355–61.
8. Sarafidis PA. Epidemiology of Resistant Hypertension. J Clin Hypertens. 2011;13(7):523–8.
9. Muxfeldt ES, Bloch KV, Da Rocha Nogueira A, Salles GF. True resistant hypertension: Is it possible to be recognized in the office? Am J Hypertens. 2005;18(12):1534–40.
10. Erdogmus S, Kutlay S, Celebi ZK, et al. Clinical Correlates of Ambulatory Blood Pressure Phenotypes at a Tertiary Care Hospital in Turkey. Kidney Blood Press Research. 2018;43(3):690-700.
11. Yavuz BB, Yavuz B, Tayfur O, et al. White coat effect and its clinical implications in the elderly. Clinical and Experimental Hypertension. 2009 Jun;31(4):306-15.
12. Piper MA, Evans C V., Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: A systematic review for the US Preventive Services Task Force. Annals of Internal Medicine. 2015 Feb 3;162(3):192-204.
13. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14(12):1263–9.
14. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring: 10-Year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46(3):508–15.
15. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 2002;40:795-6.
16. Gorostidi M, Vinyoles E, Banegas JR, De La Sierra A. Prevalence of white-coat and masked hypertension in national and international registries. Hypertens Res. 2015;38(1):1–7.
17. Peacock J, Diaz KM, Viera AJ, Schwartz JE, Shimbo D. Unmasking masked hypertension: Prevalence, clinical implications, diagnosis, correlates and future directions. J Hum Hypertens. 2014;28(9):521-8.
18. Asayama K, Thijs L, Li Y, et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension. 2014;64(5):935-42.
19. Funder JW. Primary Aldosteronism: Seismic Shifts. J Clin Endocrinol Metab. 2015 Aug;100(8):2853-5.
20. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies - A review of the current literature. 2012 Mar;44(3):157-62.
21. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: The most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811-7.
22. Muxfeldt ES, Margallo VS, Guimaraes GM, Salles GF. Prevalence and Associated Factors of Obstructive Sleep Apnea in Patients With Resistant Hypertension. Am J Hypertens. 2014 Aug;27(8):1069-78.
23. Ulasli SS, Gunay E, Koyuncu T, et al. Predictive value of Berlin Questionnaire and ESS for obstructive sleep apnea in a sleep clinic population. Clin Respir J. 2014 Jul;8(3):292-6.
24. Puretic H, Plavec D, Pavlisa G, Zuljevic E, Samarzija M, Jakopovic M. The ESS 23 years after: Is daytime sleepiness still a valid screening tool for sleep apnea. Eur Respir J. 2014;44(Suppl 58).
25. Whelton PK, Carey RM, Aronow WS, et al. 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269-1324.
26. Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019;73(23):3018–26.
27. Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: Which one is a better cardiovascular risk marker in resistant hypertension? J Hypertens. 2008 May;26(5):878-84.
28. O'Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. Journal of Hypertension. 2005, 23:697–701.
29. Muxfeldt ES, Bloch K V., Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit. 2003;8(5):181–5.
30. Danser AHJ. Renin and prorenin as biomarkers in hypertension. Curr Opin Nephrol Hypertens. 2012 Sep;21(5):508-14.